



RxFiles – Drug Comparison Charts 11th Edition (March 2017)



CHART PEARLS 11th Edition

Highlights of Just a Few of the Revisions

Guidelines Reviewed & Incorporated into Charts

ACC'16 Role of Non-Statins in CVD Risk, **ACIP'17** USA Adult & Pediatric Vaccine, **ACR'15** Rheumatoid Arthritis, **ADA'17** Diabetes Update, **AGS'15** Beers Update, **CANMAT'16** Major Depressive Disorder, **CCS'16** Dyslipidemia for CVD prevention, **CDN'15** Acne, **CHEP'16** Hypertension, **CTS'15** Asthma in Preschoolers, **SOGC'15** Contraception, **SOGC'15** Vulvovaginitis, **USPSTF'16** ASA Primary Prevention CVD/Cancer etc

Antiplatelet and Antithrombotic

Pg 17-20

- New trials: **TRITON-TIMI 38**, **TRILOGY**, **PLATO**, **PEGASUS** and **DAPT**
- DAPT Recommendations and Chart
- DOAC reversal with **PRAXBIND**

Diabetes

Pg 39-51

- New CV trials added, new drugs, updated SMBG meters

Hepatitis C

Pg 87-88

- New drugs and new treatment regimens in special populations

HIV chart

Pg 89-90

- Added new drug combos and new 2016 international guideline recommendations

Chronic Non-Cancer Pain Chart

Pg 99

- Updated neuropathic pain treatment regimens from national and international guidelines & updates from 2017 CND Opioid Guidelines

New Charts - 7 in all

- **Angina** Pg 3-4
- **DAPT & Triple Therapy** Pg 19-20
- **Bipolar in Pregnancy** Pg 149-150
- **Asthma Overview & Drug Chart** Pg 159-160
- **COPD Overview & Drug Chart** Pg 161-162
- **Drug Interactions** Pg 175-178
- **Alcohol Use Disorders** Pg 185-186

New Drug (Brand Name) Additions

ADDYI, ARNUITY ELLIPTA, BASAGLAR INSULIN, BRENZYS, BYDUREON, DAKLINZA, DOVOBET GEL, DUAKLIR, DYMISTA, ELLA, ENTRESTO, ENTYVIO, EPLUSA, FETZIMA, FORXIGA, GARDASIL 9, GENVOYA, HOLKIRA, INSPIOLTO, INVOKAMET, KAZANO, LANCORA, LIXIANA, LUNESTA, MOVANTIK, MIFEGYMISO, NATESTO, NESINA, NUCALA, PLEGRIDY, PRALUENT, PRAXBIND, REPATHA, SAVAYSA, SIMBRINZA, SPIRIVA RESPIMAT, SYNJARDY, PRALUENT, TRIUMEQ, TRULICITY, VIBATIV, XIGDUO, ZERBAXA & ZINBRYTA...

Scanning Through The Charts

- **Hypertension** – **SPRINT** trial summary pg 11-12
- **AFIB** – added new guidelines (CCS'16, ESC'16), edoxaban pg 22
- **Thyroid Disorders** – enhanced treatment information pg 55-56
- **H. Pylori Testing & Eradication** – new regimens, length of therapy & how to verify elimination pg 69
- **Irritable Bowel** – new medications (rifaximin, linaclotide) pg 70
- **CAP** – added SOAR Score pg 93-94
- **Contraceptives** – new brands, **MIFEGYMISO** pg 129-130
- **Peri-Pregnancy** – new guidelines and folic acid info pg 135-136
- **Bipolar Chart** – definitions, introduction, overview pg 147-148
- **COPD and Asthma** – new devices, more in-depth info on goals of tx, risk factors, diagnosis & triggers for each condition pg 159-163
- **Cannabinoids** – regulation changes pg 167

By the Numbers

Total pages: 206 New pages: 16 New charts: 7.

Changes: thousands. Charts updated daily, then to web/apps.

Colors and Symbols

See pg 202 (back cover) for the RxFiles risk categories.

\$ Comparisons that caught our

Generics unavailable for awhile:

Clomipramine ANAFRANIL, **Nortriptyline AVENTYL**

Hepatitis C Treatment Regimens \$/longest cycle

pg 87-88

Harvoni

\$71 K

Holkira Pak

\$112K

Zepatier

\$60 K

Substantially **REDUCED** Cost

(Also new g: **Adderall XR**, **Avelox**, **Detrol LA**, **Fosavance**, **Inflectra**, **Tecta & Vesicare**)

Levetiracetam g = KEPPRA 500mg BID

\$225 → \$120/100d

Quetiapine g = SEROQUEL 300mg BID

\$99 → \$56/30d

Isotretinoin ⊗ g = ACCUTANE, CLARUS, EPURIS

\$1020,560,730 → \$860, 445, 570/course

Doxycycline g = VIBRA-TABS 100mg OD

\$47 → \$28/4wk

Zolpidem SUBLINOX 5mg HS

\$56 → \$20/30d

Status & Reimbursement Changes

- **On SK Formulary:** **ANDROCUR**, carvedilol, **CLAVULIN**, **CLOPIXOL**, colesevelam susp, **COMBIVENT RESPIMAT**, escitalopram, gabapentin 600 & 800mg tabs, **JAYDESS**, midodrine, minocycline, **PLAN B**, & **SIMBRINZA**.
- **New EDS:** **ABILIFY MAINTENA**, **ACTEMRA** SC, **FIBRISTAL**, **ANORO & BREO ELLIPTA**, **APTOM**, **DIACOMIT**, **DIACOMIT**, **DUAKLIR GENUAIR**, **ELIQUIS**, **HARVONI**, **HOLKIRA PAK**, **INCRUSE ELLIPTA**, **INFLECTRA**, **INSPIOLTO RESPIMAT**, **INSPIRA**, **INVOKANA**, **JARDIANCE**, **KOMBOGLYZE**, **LATUDA**, **MYRBETRIQ**, **ORENCIA SC**, **PLAVIX**, **PREVACID FASTAB**, **PREZCOBIX**, **SPIRIVA RESPIMAT**, **SOVALDI**, **TIVICAY**, **TRIUMEQ**, **ULTIBRO BREEZHALER**, **VYVANSE 10MG & XELJANZ**.
- **New generics:** **AZILECT**, **BEZALIP SR**, cefixime, celecoxib, **CLINDOXYL**, duloxetine, **KIVEXA**, **NASACORT**, **OMNARIS**, **SUBOXONE**, **TAMIFLU**, **VALCYTE**, zolpidem
- **New full NIHB:** **AGGRENOX**, alendronate, **ALPHAGAN P**, **BUSPAR**, cipro susp, **CLIMARA PRO**, **CLINDOXYL**, **CLOPIXOL**, **COMBIVENT RESPIMAT**, **CYTOMEL**, **DETROL LA**, **DIVIGEL**, **EDARBI**, **EZETROL**, **FERLECIT**, **FIBRISTAL**, **FOSAVANCE**, isosorbide mononitrate, **JAYDESS**, **KEPPRA**, **LOLO**, **MONA LISA IUD**, **moxifloxacin**, **PLAN B**, **PREZCOBIX**, risendronate, **TIVICAY**, **VESICARE**, **VIGAMOX**, **VIRAMUNE XR & ZYMAR**.
- **New prior NIHB approval:** **ABILIFY MAINTENA**; **ANORO**, **BREO & INCRUSE ELLIPTA**; **APTOM**, **COSENTYX**, **DIASTAT**, **DUAKLIR**, fosfomycin, **FOSRENOL**, **GALEXOS**, **HARVONI**, **INSPIOLTO & SPIRIVA RESPIMAT**, **INFLECTRA**, **INVOKANA**, **JARDIANCE**, **KADIAN**, **KOMBOGLYZE**, **LATUDA**, **Levetiracetam**, **PENNSAID**, **SOVALDI**, **TOVIAZ**, **TURDORZA**, **ULTIBRO BREEZHALER**, **Vit E & XELJANZ**.
- **New OTC:** **ADVIL 12HR**, **FLONASE**, **OLEX & NEXIUM**

Outcome Evidence from MAJOR Trials

Major outcome trials & drug dosages used are often noted on charts when pertinent. Relatively recent: **EMPA-REG** (Empagliflozin and CV outcomes), **FLAME** (Ultibro Breezhaler vs Advair in COPD), **IMPROVE-IT** (ezetimibe + simvastatin vs simvastatin), **LEADER** (Liraglutide vs Placebo in T2DM), **PARADIGM-HF** (valsartan + sacubitril vs enalapril), **PEGASUS-TIMI** (Ticagrelor vs Placebo in patients with hx of MI), **PIONEER AF-PCI** (Rivaroxaban in A Fib), **PRECISION** (Celecoxib, ibuprofen or naproxen in osteoarthritis/RA), **SOCRATES** (Ticagrelor in stroke/ TIA vs ASA), **SPRINT** (is 120mmHg the new 140mmHg) & **SUMMIT** (Breo ellipta vs Relvar in COPD & CV patients).

Recent Adverse Reaction Advisories

Health Canada [Advisories, Warnings and Recalls - Health Canada](#) & FDA

- **ABILIFY products:** linked with impulsive behaviours like pathological gambling and hypersexuality
- **Celecoxib >200mg/d:** is linked with serious CV adverse effects similar to diclofenac $\geq 150\text{mg/d}$ and ibuprofen $>2400\text{mg/d}$
- **Domperidone:** linked with ventricular arrhythmias and sudden cardiac death
- **FORXIGA AND INVOKANA:** linked to acute kidney injury
- **Febuxostat:** HF risk warning in patients with pre-existing CV disease
- **Fluoroquinolones:** associated with retinal detachment & Tendonitis, Achilles tendon rupture & nerve damage
- **Metoclopramide:** EPS risk in children on therapeutic doses (CI in children <1yr old)
- **TECFIDERA (dimethyl fumarate):** linked with risk of PML

Pictures & Colors Speak 1000 Words

COLOURS USED WITHIN THE CHARTS

Green shading usually indicates HERBAL/LIFESTYLE related
Blue shading usually indicates PEDIATRIC related
Dark Blue shading usually indicates ADOLESCENT related
Tan shading usually indicates ELDERLY related
Purple script usually indicates TRADE NAMES
Yellow highlights CLINICAL DIFFERENCES, PRACTICE GAPS & COMMON ?'s
Blue script usually indicates MAJOR TRIALS
Pink script usually indicates PREGNANCY & LACTATION related
Red shading usually indicates official FDA black box or HC warning
Gray script usually indicates DISCONTINUED drug
Purple shading usually indicates OVERVIEW/GUIDELINE approach

☺ Your notes...

COMMONLY USED ABBREVIATIONS

AE	Adverse event
BID	Twice daily
BP	Blood pressure
Bz	Benzodiazepine
CI	Contraindication
CV	Cardiovascular
DI	Drug interaction
Dx	Diagnosis/disease
HSR	Hypersensitivity reaction
LFT	Liver function tests
M	Monitoring
OTC	Over the counter
p	Porphyria
QID	Four times daily
eGFR	Estimated glomerular filtration rate
g	Generic available
GI	Gastrointestinal
HA	Headache
HF	Heart failure
HR	Heart rate
HS	Bedtime
SCr	Serum creatinine
SJS	Stevens Johnson Syndrome
Sx	Syndrome/symptom
Sz	Seizure
TID	Three times daily
Tx	Treatment/Therapy



RxFiles Online www.RxFiles.ca

- **FREE Newsletters, Q&As, Trial Summaries** to all
 - Updated charts and RxFiles+ app available to those with subscription/ group subscription or SHIRP account
 - Links / Program Information / References / Search Feature / Online Store / **iPad, iPhone, Android**
 - RxFiles **Email Notification** of new postings
 - All Charts sizes (pocket, standard & oversized) are tabbed
 - **Link to order form:** <http://www.rxfiles.ca/rxfiles/uploads/documents/1A-CHT-Book-ORDERFORM.pdf>
- Editors: Brent Jensen, Loren Regier & Lynette Kosar

SYMBOLS

	Canada (We are Canadian)
	Non-formulary in Saskatchewan
	Exception Drug Status (EDS) in Saskatchewan (SK) (1-800-667-2549)
	Not covered by NIHB (Non-Insured Health Benefits) http://www.hc-sc.gc.ca/fnihb/nihb/pharmacy/drugbenefitlist/index.htm
	Prior approval required by NIHB . Coverage for eligible First Nations & Inuit (1-800-580-0950)
	Covered by NIHB. Found on the OTC charts (pgs 135-138) & identified ONLY for those drugs which have SK Formulary restrictions such as EDS or non-formulary status .
	Retail <i>Cost to Consumer</i> based on acquisition cost, markup & dispensing fee in Saskatchewan. Lowest generic price used where available.
	Free Medication coverage provided by the Saskatchewan Cancer Centre
	Warfarin interactions on the herbal chart
	Tablet is scored. Appears as superscript, e.g. 25 ^s mg tablet.
	Tastes good
	Concern if drug or herbal is given Pre-Op
	Avoid if patient has soybean & peanut allergy
	Male
	Female
	Dose ↓ may be required for liver dysfunction
	Dose ↓ required for renal dysfunction if 1) drug $\geq 75\%$ renal excretion 2) toxic if accumulates 3) an active metabolite requiring dose adjustment. [CrCl <60ml/min indicates impaired renal function]

DRUGS IN PREGNANCY & LACTATION RISK CATEGORIES

PREGNANCY [P]	LACTATION [L]
Safe	Safe
<ul style="list-style-type: none"> • Compatible in pregnancy 	<ul style="list-style-type: none"> • Compatible in breastfeeding
Likely Safe	Likely Safe
<ul style="list-style-type: none"> • No (limited) human data – probably compatible • Compatible: maternal benefit >> embryo-fetal risk • Human data suggest low risk 	<ul style="list-style-type: none"> • No (limited) human data – probably compatible
Caution	Caution
<ul style="list-style-type: none"> • Human, and or animal, data suggest risk • Potential risk in specific trimester(s), as indicated by 'x' 	<ul style="list-style-type: none"> • Hold/delay breastfeeding • No (limited) human data – potential toxicity
Contraindicated	Contraindicated
<ul style="list-style-type: none"> • Contraindicated in pregnancy • Contraindicated in specific trimester(s), as indicated by 'x' 	<ul style="list-style-type: none"> • Contraindicated in breastfeeding
Unknown for Pregnancy and/or Lactation	
<ul style="list-style-type: none"> • No (limited) human data – no relevant animal data 	
Reference: Drugs in Pregnancy and Lactation. 10 th ed. Briggs GE, Freeman RK, Yaffe SJ, editors. Williams and Wilkins; Philadelphia, PA: 2011.	<p>What you'll see in the charts: P = pregnancy L = lactation risk category Colours correspond to risk categories outlined in this table. Example, warfarin: P = contraindicated 1st trimester L = compatible during lactation</p>